Aurinia Historical Balance Sheet
AUPH Stock | USD 8.86 0.01 0.11% |
Trend analysis of Aurinia Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 102.5 M, Other Current Liabilities of 38 M or Total Current Liabilities of 81 M provides information on Aurinia Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Aurinia Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Aurinia Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Aurinia Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aurinia Pharmaceuticals is a good buy for the upcoming year.
Aurinia Pharmaceuticals Inventory |
|
Aurinia |
About Aurinia Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Aurinia Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Aurinia Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aurinia Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aurinia currently owns. An asset can also be divided into two categories, current and non-current.
Aurinia Pharmaceuticals Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Aurinia Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aurinia Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Aurinia Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aurinia Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Liabilities And Stockholders Equity
The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.Most accounts from Aurinia Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Total Current Liabilities is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Total Stockholder Equity is estimated to increase to about 396.9 M, while Retained Earnings are forecasted to increase to (895.2 M).
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 8.7M | 8.1M | 97.6M | 102.5M | Total Assets | 543.4M | 470.9M | 548.1M | 575.5M |
Aurinia Pharmaceuticals balance sheet Correlations
Click cells to compare fundamentals
Aurinia Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aurinia Pharmaceuticals balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.7M | 463.7M | 543.4M | 470.9M | 548.1M | 575.5M | |
Other Current Liab | 118K | 27.8M | 33.8M | 37.4M | 36.2M | 38.0M | |
Total Current Liabilities | 11.3M | 32.0M | 40.6M | 46.1M | 77.2M | 81.0M | |
Total Stockholder Equity | 273.5M | 407.8M | 479.1M | 405.4M | 378.0M | 396.9M | |
Property Plant And Equipment Net | 93K | 10.3M | 9.8M | 8.6M | 116.6M | 122.4M | |
Net Debt | (306.0M) | (263.9M) | (223.2M) | (86.1M) | 48.7M | 51.2M | |
Retained Earnings | (539.8M) | (575.2M) | (756.1M) | (864.3M) | (942.3M) | (895.2M) | |
Accounts Payable | 4.2M | 2.6M | 3.9M | 3.1M | 4.3M | 3.3M | |
Non Current Assets Total | 11.5M | 44.2M | 30.0M | 28.3M | 123.3M | 129.4M | |
Net Receivables | 368K | 1.0M | 15.4M | 13.5M | 24.1M | 25.3M | |
Common Stock Shares Outstanding | 93.0M | 118.5M | 129.4M | 141.9M | 143.2M | 150.4M | |
Liabilities And Stockholders Equity | 326.7M | 463.7M | 543.4M | 470.9M | 548.1M | 575.5M | |
Non Current Liabilities Total | 41.9M | 23.9M | 23.6M | 19.3M | 92.9M | 97.6M | |
Other Current Assets | 8.8M | 7.2M | 12.5M | 14.9M | 10.5M | 11.0M | |
Other Stockholder Equity | 23.7M | 39.4M | 59.0M | 85.5M | 120.8M | 66.4M | |
Total Liab | 53.2M | 55.9M | 64.3M | 65.4M | 170.1M | 178.6M | |
Property Plant And Equipment Gross | 93K | 10.3M | 9.8M | 8.6M | 118.5M | 124.4M | |
Total Current Assets | 315.1M | 419.4M | 513.3M | 442.5M | 424.8M | 446.0M | |
Short Term Debt | 6.9M | 1.6M | 2.1M | 1.9M | 31.2M | 32.8M | |
Intangible Assets | 11.2M | 9.3M | 8.4M | 6.4M | 5.0M | 7.0M | |
Cash | 306.0M | 272.4M | 231.9M | 94.2M | 48.9M | 66.4M | |
Non Currrent Assets Other | 209K | 247K | 11.8M | 13.3M | 1.5M | 2.9M | |
Cash And Short Term Investments | 306.0M | 398.3M | 466.1M | 389.4M | 350.5M | 368.0M | |
Other Liab | 14.4M | 16.3M | 16.0M | 12.2M | 14.0M | 7.3M | |
Net Tangible Assets | 289.7M | 398.4M | 470.7M | 399.0M | 458.9M | 481.8M | |
Other Assets | 209K | 5.7M | 11.8M | 13.3M | 15.3M | 16.1M | |
Common Stock Total Equity | 504.7M | 790.5M | 944.3M | 1.2B | 1.4B | 1.4B | |
Common Stock | 790.5M | 944.3M | 1.2B | 1.2B | 1.2B | 1.3B | |
Property Plant Equipment | 93K | 4.8M | 9.8M | 8.6M | 7.7M | 8.1M | |
Capital Surpluse | 24.7M | 23.7M | 39.4M | 59.0M | 67.9M | 71.3M | |
Non Current Liabilities Other | 12.3M | 1.6M | 16.0M | 12.2M | 10.9M | 8.8M | |
Net Invested Capital | 273.5M | 407.8M | 479.1M | 405.4M | 378.0M | 349.2M |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.